Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Prostatic Neoplasms

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

This is a minimally invasive procedure for focal treatment of prostate cancer.

Laser Interstitial Thermal Therapy

Pantuck Alan, MD

Steven Raman, MD

This is a pilot, feasibility/exploratory study to evaluate the safety of laser interstitial thermal therapy (LITT) using Visualase in the focal treatment of localized prostate cancer as well as to gather data for the design of future studies.

Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer

Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study

Jonsson Comprehensive Cancer Center

Blood and Lymph Conditions

Mouth and Tooth Diseases

Digestive System Diseases

Hematologic Neoplasms

Stomatitis

Mucositis

Hematologic Diseases

Gastroenteritis

Gastrointestinal Diseases

Mouth Diseases

Stomatognathic Diseases

preventive treatment performed by nurses of mucositis by laser treating daily by scanning the entire oral cavity for 2 minutes with a power of 250 mW associated with mouthwashes several times a day (standard preventive treatment of mucositis)

daily laser-off session performed by nurses associated with mouthwashes several times a day (standard preventive treatment of mucositis)

Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.

If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only.

Laser treatment

Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.

If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only.

Placebo

Emmanuelle TAVERNIER, MD

The LLLT has an anti-inflammatory, analgesic effect and accelerates the healing of ulcerated lesions. There are little data in the literature showing its efficacy in prevention of mucositis in cohorts of patients with hematopoietic stem cells transplantation.

The main objective of this study is to assess the efficacy of a prophylactic low level laser therapy performed by nurses on the severity of oral mucositis during HSCT.

The main end point for efficacy is the reduction of severe mucositis (grade 3 or more). The secondary efficacy endpoints are the reduction of mucositis, whatever the grade, the reduction of time with mucositis, the time to onset of mucositis symptoms, the reduction of pain intensity and evaluation of quality of life.The secondary endpoints for safety are severe adverse events and potential toxicity. Patients will be allocated at inclusion with a 1/1 ratio either to laser-on or laser-off groups. In the laser group, patients will undergo laser therapy performed by nurses, which will consist of irradiation of the whole oral cavity during 2 minutes with 250mW power. In the laser-off group, laser therapy will be carried out with equipment off during the same time, and still performed by nurses. Protective eye shields will be used to avoid detrimental effects on eyes and to keep the subjects blind.

Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation

Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation : a Randomized Double Blind Multicenter Prospective Phase III Trial

prevalence of grade 3 and more mucositis following the classification proposed by WHO (world health organization)

The number of all grades of mucositis will be reported at day 30 post graft for all patients.

The duration of mucositis will be reported at day 30 post graft for all patients.

time of onset of mucositis will be assessed by measuring the interval between the beginning of packaging and the first day of mucositis has been assessed at a grade 1

Pain will be reported for each patient during their participation: 30 days post graft maximum.

Quality of life will be reported for each patient during their participation: 30 days post graft maximum.

serious adverse events will be reported for each patient during their participation: 30 days post graft maximum.

Hospices Civils de Lyon

Centre Leon Berard

Société Biophoton

Institut de Cancérologie de la Loire

Infections

Skin and Connective Tissue Diseases

Symptoms and General Pathology

Warts

Communicable Diseases

Papillomavirus Infections

Virus Diseases

DNA Virus Infections

Skin Diseases

Skin Diseases, Viral

Tumor Virus Infections

Skin Diseases, Infectious

a maximum of 4 sessions, with an interval of 3 to 4 weeks

laser treatment

cryotherapy

Shichao Lu, MD

To evaluate whether laser was superior to cryotherapy for recalcitrant warts

Patients with recalcitrant warts were randomized equally to receive laser or cryotherapy every 3 to 4 weeks, for a maximum of 4 sessions.The primary outcomes were the cure rate at 16 weeks; secondary outcomes included time to clearance of warts, patient satisfaction with the treatment and treatment-related adverse effects.

Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts

Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts: a Randomised Controlled Trial

A patient was considered to be cured if all warts were no longer visible and could not be palpated anymore.

The time from treatment initiation until clearance of all warts

Patient satisfaction was rated on a 5-point scale (from very happy to very unhappy)

Some adverse effects, including pain, swelling, blisters, hemorrhagic bullae, bruising, and skin breakdown, were recorded by the patients, whereas others, including secondary bacterial infection, hyperpigmentation, hypopigmentation, and scarring were evaluated by a dermatologist

The 306 Hospital of People's Liberation Army

Skin Neoplasms

Cicatrix

Group 1 will receive laser therapy to half of the scar the day of the excision.

Group 2 will receive laser therapy at the time of suture removal or post-operative day 14.

Group 3 will receive laser treatment to half the scar at the 9 week postop visit.

The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.

Laser Treatment

Hooman Khorasani, MD

The purpose of this study is to evaluate the potential benefits of treating a surgical scar post excision with an ablative fractionated CO2 laser with the goal of decreasing the appearance and size of the scar.

The objective of this research is to determine, through a split scar study, that treating a post excision scar with a fractionated ablative CO2 laser improves both the texture and cosmetic appearance of the scar. An attempt will be made to determine the ideal timing for treating the excision scar as previous studies have ranged from treating the day of the excision up till 10 weeks post-excision. In order to evaluate the treated portion versus untreated portion of the scar, investigators and the subjects will use a quartile rating scale. In addition, punch biopsy samples will be taken to quantify the difference in collagen architecture 9 weeks after treatment with the laser.

There will be a total of 7 study visits to include the day of the excision and laser treatment if randomized to this group, post-op day number 14 for suture removal as well as laser therapy if the subject has been randomized to that treatment group, 4 weeks post-op, 9 weeks post-op and laser treatment for subjects randomized to this time frame for treatment, 12 weeks post-op, 17 weeks post-op and 24 weeks post-op. Each visit will last approximately 30-45 minutes each in which clinical photos of the surgical scar will be taken and any wound care or side effects of the laser therapy or surgery will be addressed. Healing and scar appearance will be reviewed and rated at each of the six postsurgical visits.

Post Excision/Mohs Scar Laser Resurfacing

Post Excision/Mohs Fractional CO2 Resurfacing: A Quantitative and Qualitative Scar Analysis Study

modified Manchester scar scale (MMSS) treated - Full scale from 5 to 18, with higher score indicating lower health outcomes

Fd indicates scar tissue density - a measure of how completely an object fills space and increases in value with increasing structural density. It has a value between 1 and 2: a minimum value of 1 corresponds to a straight line filling the space, and a maximum value of 2 corresponds to an object completely occupying the entire space.

Lacunarity describes the characteristics of fractals of the same dimension with different texture appearances and indicates scar tissue architecture (homogeneous vs. heterogeneous) - a measure of the nonuniformity (heterogeneity) of a structure or the degree of structural variance within an object. L has a value between 0 and 1, where a minimum value of 0 corresponds to an absolute homogeneous object.

Comparison of scars using quartile scale: 0 indicates no difference, 1 indicates a 1-25% difference or "mild" difference, 2 indicates a 26-50% or moderate difference, 3 indicates a 51-75% or significant improvement and 4 indicates a 76-100% difference or very significant.

Icahn School of Medicine at Mount Sinai

Clinical Professor

Participants with wounds to limbs of Fitzpatrick skin phototype I or II to receive laser therapy to half of the scar the day of the excision, Day 0; and to the other half on Day 14.

Participants With Fitzpatrick Skin Phototype I or II

Age, Continuous

Sex: Female, Male

Race (NIH/OMB)

Scar length

Single-center study with wounds limited to limbs of skin phototype I-II subjects.

Dr. Hooman Khorasani

Day 0

Day 14

MMSS for Scar Halves Treated

Fractal dimension (Fd) Day 0

Fractal dimension (Fd) Day 14

Lacunarity Day 0

Lacunarity Day 14

Quantitative Scar Analysis as Measured by Fractal Dimension (Fd) and Lacunarity

Quartile Scale

Overall Study

Urinary Bladder Neoplasms

Urologic Neoplasms

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Intervention is diode laser treatment of bladder cancer through a cystoscope without sedation of the patient.

Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department

Gregers G Hermann, MD

Laser treatment of pTa low grade bladder tumours in the outpatient department

Number of Subjects/Centres Planned: 20 patients will be included in this study. The study will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.

Primary Objective: To show that small pTa bladder tumours safely can be removed with diode laser in an outpatient department Secondary Objective: To evaluate the patients experience with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog Scale Score (pain evaluation).

Laser treatment of pTa low grade bladder tumours in the outpatient department

Number of Subjects/Centres Planned: 20 patients will be included in this study. The study will be performed at Department of Urology, Bispebjerg-Frederiksberg Hospital, Copenhagen, Denmark.

Primary Objective: To show that small pTa bladder tumours safely can be removed with diode laser in an outpatient department Secondary Objective: To evaluate the patients experience with the laser treatment using QOL questionaires (symptom evaluation) and Visual Analog Scale Score (pain evaluation).

Study Design: Open prospective study in patients with recurrent pTa low grade bladder tumours.

All patients will have their bladder tumour removed using a diode laser. The treatment will take place in the outpatient department (OPD) without any pain treatment. Biopsy from the tumour will be obtained before the procedure. If the biopsy shows low grade non-invasive bladder tumour, flexible cystoscopy will be repeated one month later in the OPD. At both procedures biopsy will be taken from the laser treated area.

If the per-operative biopsy shows high grade or invasive tumour, the patient will be referred for a re-resection at the operating theatre during admittance to the urology ward.

The pain is valuated by a Visual Analogue Scale Score and filled out immediately after each procedure.

Treatment induced symptoms will be evaluated using a QOL questionnaire which the patient fills out one week after the laser treatment and one week after the cystoscopies.

Population: Patients with histologically confirmed pTa urothelial bladder tumours Number of Subjects: Twenty patients Selection of Subjects: Patients scheduled for a trans urethral resection of bladder tumour (TUR-B) less than 1,5 cm at the operating theatre under general anaesthesia and without concomitant therapy with anticoagulants as Marevan, Marcoumar, and the new anticoagulants as Pradaxa etc. will after informed consent be included in the study.

Equipment:

Diode laser Storz, SPIES Biopsy forceps, Storz

Key Dates:

Overall duration of the study: 6 months included 1 months follow up Efficacy and Safety Variables Primary Endpoint: proportion of patients where the bladder tumours are completely removed by one laser treatment.

Secondary Endpoints:

* Portion of general urinary problems and QOL after laser treatment compared to cystoscopy and biopsy in the OPD
* Pain at the laser treatment and the cystoscopy assessed by Visual Analog Scale (VAS) Score.

Statistical Methods and Planned Analysis: Non-parametric and descriptive statistics will be performed

Parameters in the case report form (CRF):

Bladder cancer diagnosis (pTa low grade)

* Age
* Sex
* Mapping of lesions in normal, Clara Chrome, Spectra A and B filter cystoscopy
* Histology of all suspicious lesions
* SEPARATE CYSTOSCOPYFORM for laser TUR-B and the two follow up cystoscopies
* The duration of the laser treatment
* Expected clearance after the laser TUR-B
* The visibility during the laser TUR-B
* Visual Analog Scale Score result (to measure pain when laser treatment is performed and biopsies are taken in the OPD)

Diode Laser Treatment of Bladder Tumors

Diode Laser Treatment of Pta Low Grade Bladder Tumors in the Outpatient Department.

No bladder tumor tissue in biopsies obtained from areas where a bladder tumor one month earlier has been removed by use of diode laser.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer	NCT02224911	Prostate Cancer	Laser Interstit...	40 Years - 85 Years	Jonsson Comprehensive Cancer Center
Efficacy of Prophylactic Low Level Laser Therapy (LLLT) Performed by Nurses for Decreasing Severity of Oral Mucositis During Hematopoietic Stem Cell (HSC) Transplantation	NCT02696408	Hematologic Mal...	Laser treatment Placebo	18 Years -	Institut de Cancérologie de la Loire
Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts	NCT05616078	Warts	laser treatment cryotherapy	18 Years -	The 306 Hospital of People's Liberation Army
Post Excision/Mohs Scar Laser Resurfacing	NCT02130297	Skin Cancer	Laser Treatment	18 Years -	Icahn School of Medicine at Mount Sinai
Diode Laser Treatment of Bladder Tumors	NCT02738827	Bladder Cancer	Laser treatment	18 Years -	University Hospital Bispebjerg and Frederiksberg
Diode Laser Treatment of Bladder Tumors	NCT02738827	Bladder Cancer	Laser treatment	18 Years -	University Hospital Bispebjerg and Frederiksberg

Spots Global Cancer Trial Database for laser treatment